Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
123.62
-1.05 (-0.84%)
At close: Oct 31, 2025, 4:00 PM EDT
122.95
-0.67 (-0.54%)
After-hours: Oct 31, 2025, 5:39 PM EDT
Abbott Laboratories Stock Forecast
Stock Price Forecast
The 18 analysts that cover Abbott Laboratories stock have a consensus rating of "Strong Buy" and an average price target of $146.61, which forecasts a 18.60% increase in the stock price over the next year. The lowest target is $135 and the highest is $162.
Price Target: $146.61 (+18.60%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Abbott Laboratories stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 9 | 9 | 9 | 9 |
| Buy | 8 | 8 | 8 | 8 | 8 | 7 |
| Hold | 4 | 4 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 20 | 20 | 20 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $159 → $162 | Buy | Maintains | $159 → $162 | +31.05% | Oct 17, 2025 |
| Raymond James | Raymond James | Buy Maintains $141 → $146 | Buy | Maintains | $141 → $146 | +18.10% | Oct 16, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $144 → $142 | Buy | Maintains | $144 → $142 | +14.87% | Oct 16, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $147 | Buy | Reiterates | $147 | +18.91% | Oct 16, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $142 → $146 | Buy | Maintains | $142 → $146 | +18.10% | Oct 16, 2025 |
Financial Forecast
Revenue This Year
45.12B
from 41.95B
Increased by 7.56%
Revenue Next Year
48.63B
from 45.12B
Increased by 7.78%
EPS This Year
5.20
from 7.64
Decreased by -31.88%
EPS Next Year
5.74
from 5.20
Increased by 10.25%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 47.0B | 51.0B | |||
| Avg | 45.1B | 48.6B | |||
| Low | 43.7B | 46.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.0% | 13.0% | |||
| Avg | 7.6% | 7.8% | |||
| Low | 4.1% | 3.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.44 | 6.07 | |||
| Avg | 5.20 | 5.74 | |||
| Low | 5.04 | 5.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -28.8% | 16.6% | |||
| Avg | -31.9% | 10.2% | |||
| Low | -34.1% | 6.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.